Company news, research breakthroughs, and major announcements across industries.

Home/Health

Health |Pfizer’s TUKYSA Regimen

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer

Pfizer
Pfizer

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expands the use of TUKYSA to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance treatment option that may help further delay disease progression.

  • PublishedOctober 7, 2026 · 12:57 PM
  • LocationNEW YORK
  • IndustryHealth
  • LanguageEN

Published by Business Wire. Read the original announcement for the full release.

Read the full announcement →

Latest from leading organizations

Explore recent announcements by organization